Home » Newsletters » BioWorld Science

BioWorld Science

May 10, 2011

View Archived Issues

Novel CRAC inhibitors presented

New antibacterial aminoglycoside derivatives claimed

Merck & Co. patents new gamma-secretase inhibitors

Merrimack regains rights to nanoliposomal irinotecan from PharmaEngine

Favorable preclinical data disclosed on HSP 90 inhibitor MPC-3100

Compound 49b shows promise to treat diabetic retinopathy

Ophthalmic antimicrobial peptide SESB-88V inhibits ocular pathogens

Clinical study finds omalizumab ineffective in treating eosinophilic esophagitis

Intravenous solithromycin is well tolerated in healthy volunteers

Novel tyrosine-protein kinase JAK inhibitors patented by Pfizer

Rib-X Pharmaceuticals discloses new antibacterial agents

New ALK tyrosine kinase receptor inhibitors presented

Institute of Human Virology receives funding for HIV vaccine candidate FLSC

Opsona Therapeutics receives EC grant for clinical development of OPN-305

Chelsea Therapeutics receives approval to open new arm in phase II CH-4051 trial

Astellas and Medivation begin new phase II MDV-3100 trial in prostate cancer

MCD-386CR receives FDA orphan drug status in progressive supranuclear palsy

Wilex completes patient recruitment in phase II Mesupron trial

Alcon Research begins phase II study of AL-59412C

Takeda and Pronova report on pivotal Japanese trial of TAK-085 in hypertriglyceridemia

FDA approves Sanofi Pasteur's new intradermal injection of Fluzone influenza vaccine

Actikerall enters national approval phase in seven European countries for actinic keratosis

EpiCept files protocol for confirmatory phase III Ceplene trial in AML

Bayer's regorafenib receives FDA fast track status in GIST

CCL21-vaults have antitumor effects in model of lung cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 12, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
LINC01116 has prognostic value in lung cancer, study shows
BioWorld Science
Long noncoding RNAs (lncRNAs) have emerged as potential markers of disease, since they associate with proteins that regulate gene expression, translation or...
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...